Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-02-23
2010-02-02
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C530S324000
Reexamination Certificate
active
07655237
ABSTRACT:
Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic disease, arterial hypertension and functional ovaric hyperandrogenism.
REFERENCES:
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5804189 (1998-09-01), Goyert
patent: 5869055 (1999-02-01), Juan et al.
patent: 6319245 (2001-11-01), Berrigan
patent: WO 92/04908 (1992-04-01), None
patent: WO 92/04908 (1992-04-01), None
patent: WO 93/19772 (1993-10-01), None
patent: WO 93/19772 (1993-10-01), None
patent: WO 00/53165 (2000-09-01), None
patent: WO 00/53165 (2000-09-01), None
patent: WO 0053165 (2000-09-01), None
The Merck Manual of Diagnosis and Therapy, 17th edition, 1999, Diabetes Mellitus, pp. 165-177.
The Merck Manual of Diagnosis and Therapy, 17th edition, 1999, Arteriosclerosis, pp. 1654-1659.
Koenig Wolfgang et al: CD14 C(-260) fwdarwT Polymorphism, Plasma Levels of the Soluble Endotoxin Receptor CD14, their Association with Chronic Infections an Risk of Stable Coronary Artery Disease, Journal of the American College of Cardiology, Jul. 3, 2002, pp. 34-42, vol. 40, No. 1.
Marques-Vidal Pedro et al: Prevalence of Insulin Resistance Syndrome in Southwestern France and its Relationship with Inflammatory and Hemostatic Markers, Diabetes Care, Aug. 2002, pp. 1371-1377, vol. 25, No. 8.
Hubacek J A et al: C(-260) T Polymorphism in the Promoter of the CD14 Monocyte Receptor Gene as a Risk Factor for Myocardial Infarction, Circulation, American Heart Associtation, 1999, pp. 3218-3220, vol. 99, Dallas, TX, US.
Communication under Rule 71(3) EPC, Mar. 20, 2008, European Patent Office.
Decision to Grant a European Patent Pursuant to Article 97(1) EPC, Jul. 31, 2008, European Patent Office.
Koenig, Wolfgang et al., CD14 C(-260) →T Polymorphism, Plasma Levels of the Soluble Endotoxin Receptor CD14, Their Association with Chronic Infections and Risk of Stable Coronary Artery Disease, Journal of the American College of Cardiology, 2002, pp. 34-42, vol. 40, No. 1, Elsevier Science Inc.
Marques-Vidal, Pedro et al., Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship with Inflammatory and Hemostatic Markers, Diabetes Care, Aug. 2002, pp. 1371-1377, vol. 25, No. 8.
Hubacek, Jaroslav A. et al., C(-260) →T Polymorphism in the Promoter of the CD14 Monocyte Receptor Gene as a Risk Factor for Myocardial Infarction, Brief Rapid Communications, 1999, pp. 3218-3220, vol. 99.
Schreyer, Sandra A. et al., Obesity and Diabetes in TNF-α Receptor-deficient Mice, J.Clin.Invest, Jul. 1998, pp. 402-411, vol. 102, No. 2.
Jacob, Chaim O. et al., Prevention of Diabetes in Nonobese Diabetic Mice by Tumor Necrosis Factor (TNF): Similarities Between TNF-α and Interleukin 1, Proc.Natl.Acad.Sci.USA, Feb. 1990, pp. 968-972, vol. 87.
International Search Report for the International Application No. PCT/EP/2004/050189, European Patent Office, Jun. 16, 2005.
Written Opinion of the International Searching Authority for the International Application No. PCT/EP/2004/050189, European Patent Office. Jun. 14, 2005.
Communication Pursuant to Article 96(2) EPC, Dec. 19, 2006, European Patent Office.
Reply to Examination Report, Amended Claims and General Enquiry, Jun. 20, 2007.
Engel Wifredo
Fernandez-Real José
Berebbaum Weinshienk PC
Bridge Bioresearch Limited
Kalan Kristina M.
Scull Peter B.
Szperka Michael
LandOfFree
Use of soluble CD14 for treatment of type 2 diabetes mellitus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of soluble CD14 for treatment of type 2 diabetes mellitus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of soluble CD14 for treatment of type 2 diabetes mellitus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195341